Form 10 Explorer
10-K
Annual Report
Actuate Therapeutics, Inc.

ACTU

NASDAQ

CIK: 1652935

File #: 001-42139

Period End: Dec 31, 2024

Fiscal Year: 2024

View on EDGAR
Balance Sheet
34 line items · 2 periods
XBRL
ItemDec 31, 2024Dec 31, 2023
ASSETS
Current assets:
Cash and Cash Equivalents
8,641,6222,958,659
Other Non-Operating Current Assets
566,27836,907
Total current assets
9,207,9002,995,566
Other Non-Operating Non-Current Assets
110,5480
Total assets
9,318,4482,995,566
LIABILITIES, REDEEMABLE CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS’ EQUITY (DEFICIT)
Current liabilities:
Accounts Payable
1,921,1893,421,840
Other Non-Operating Current Liabilities
5,921,9083,221,254
Other Current Liabilities
888,449277,500
Other Non-Operating Current Liabilities
70,9570
UIC License Agreement
70,957
Total current liabilities
8,802,5036,920,594
Long term liabilities:
Other Non-Operating Non-Current Liabilities
0988,049
Other Non-Operating Current Liabilities
6,768130,041
UIC License Agreement
77,725130,041
Other Non-Operating Current Liabilities
404,991404,991
Total long-term liabilities
411,7591,523,081
Total liabilities
9,214,2628,443,675
Temporary Equity
094,178,404
Stockholders’ equity (deficit):
Preferred Stock
00
Total Stockholders' Equity
202
Total Stockholders' Equity
132,484,0155,468,006
Total Stockholders' Equity
(132,379,849)(105,094,521)
Total stockholders’ equity (deficit)
104,186(99,626,513)
Redeemable Convertible Preferred Stock
94,178,404
Common Stock
202
Additional Paid-in Capital
132,484,0155,468,006
Retained Earnings
(132,379,849)(105,094,521)
Total liabilities, redeemable convertible preferred stock and stockholders’ equity (deficit)
9,318,4482,995,566